These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 23148794)
1. Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes. Amoah V; Storey RF; Worrall AP; Goodridge K; Lovatt T; Smallwood A; Armesilla AL; Nevill AM; Cotton JM Platelets; 2013; 24(8):643-8. PubMed ID: 23148794 [TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC; Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498 [TBL] [Abstract][Full Text] [Related]
3. Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. Bonello L; Camoin-Jau L; Mancini J; Bessereau J; Grosdidier C; Alessi MC; Ostorero M; Dignat-George F; Paganelli F Thromb Res; 2012 Jul; 130(1):70-4. PubMed ID: 22285300 [TBL] [Abstract][Full Text] [Related]
4. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients. Tang N; Yin S; Sun Z; Xu X; Qin J Scand J Clin Lab Invest; 2015 May; 75(3):223-9. PubMed ID: 25594796 [TBL] [Abstract][Full Text] [Related]
5. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. Price MJ; Murray SS; Angiolillo DJ; Lillie E; Smith EN; Tisch RL; Schork NJ; Teirstein PS; Topol EJ; J Am Coll Cardiol; 2012 May; 59(22):1928-37. PubMed ID: 22624833 [TBL] [Abstract][Full Text] [Related]
6. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793 [TBL] [Abstract][Full Text] [Related]
7. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Marcucci R; Giusti B; Paniccia R; Gori AM; Saracini C; Valente S; Giglioli C; Parodi G; Antoniucci D; Gensini GF; Abbate R Platelets; 2012; 23(8):586-93. PubMed ID: 22390861 [TBL] [Abstract][Full Text] [Related]
8. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Tang XF; Zhang JH; Wang J; Han YL; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ Chin Med J (Engl); 2013 Mar; 126(6):1069-75. PubMed ID: 23506580 [TBL] [Abstract][Full Text] [Related]
9. Genetic determinants of response to clopidogrel and cardiovascular events. Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L; N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083 [TBL] [Abstract][Full Text] [Related]
10. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study. Palmerini T; Calabrò P; Piscione F; De Servi S; Cattaneo M; Maffeo D; Toso A; Bartorelli A; Palmieri C; De Carlo M; Capodanno D; Barozzi C; Tomasi L; Della Riva D; Mariani A; Taglieri N; Reggiani LB; Bianchi R; De Rosa R; Mariani M; Podda G; Généreux P; Stone GW; Angiolillo DJ JACC Cardiovasc Interv; 2014 Oct; 7(10):1117-27. PubMed ID: 25240538 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Carlquist JF; Knight S; Horne BD; Huntinghouse JA; Rollo JS; Muhlestein JB; May H; Anderson JL Thromb Haemost; 2013 Apr; 109(4):744-54. PubMed ID: 23364775 [TBL] [Abstract][Full Text] [Related]
12. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. Frére C; Cuisset T; Gaborit B; Alessi MC; Hulot JS J Thromb Haemost; 2009 Aug; 7(8):1409-11. PubMed ID: 19496924 [No Abstract] [Full Text] [Related]
13. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel]. Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044 [TBL] [Abstract][Full Text] [Related]
14. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. Namazi S; Kojuri J; Khalili A; Azarpira N Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638 [TBL] [Abstract][Full Text] [Related]
15. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009 [TBL] [Abstract][Full Text] [Related]
16. CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel. Peters BJ; Harmsze AM; ten Berg JM; Maitland-van der Zee AH; Tjoeng MM; de Boer A; Deneer VH Pharmacogenomics; 2011 Feb; 12(2):141-4. PubMed ID: 21332306 [No Abstract] [Full Text] [Related]
17. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Malek LA; Kisiel B; Spiewak M; Grabowski M; Filipiak KJ; Kostrzewa G; Huczek Z; Ploski R; Opolski G Circ J; 2008 Jul; 72(7):1165-9. PubMed ID: 18577829 [TBL] [Abstract][Full Text] [Related]
18. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367 [TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. Tello-Montoliu A; Jover E; Marín F; Bernal A; Lozano ML; Sánchez-Vega B; Pastor FJ; Hurtado JA; Valdés M; Vicente V; Rivera J Rev Esp Cardiol (Engl Ed); 2012 Mar; 65(3):219-26. PubMed ID: 22116003 [TBL] [Abstract][Full Text] [Related]
20. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Ono T; Kaikita K; Hokimoto S; Iwashita S; Yamamoto K; Miyazaki Y; Horio E; Sato K; Tsujita K; Abe T; Deguchi M; Tayama S; Sumida H; Sugiyama S; Yamabe H; Nakamura S; Nakagawa K; Ogawa H Thromb Res; 2011 Dec; 128(6):e130-6. PubMed ID: 21862109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]